, Volume 74, Issue 4, pp 465-488
Date: 07 Mar 2014

QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

QVA149 (indacaterol/glycopyrronium) [Xoterna® Breezhaler®, Ultibro® Breezhaler®] is an inhaled fixed-dose combination of indacaterol (a long-acting selective β2-adrenergic receptor agonist [LABA]) and glycopyrronium (a long-acting muscarinic receptor antagonist [LAMA]) that has been approved in the EU and Japan for the symptomatic control of chronic obstructive pulmonary disease (COPD) in adults. In phase III studies, QVA149 significantly improved bronchodilation versus indacaterol, glycopyrronium or tiotropium alone and the LABA/inhaled corticosteroid fixed-dose combination salmeterol/fluticasone. These improvements in lung function, which were rapid in onset and maintained during long-term treatment, were generally associated with significant improvements in dyspnoea, health status, COPD exacerbation risk, patient symptoms, and rescue medication use. The SHINE and ILLUMINATE studies in low (exacerbation) risk patients with moderate to severe disease suggest that QVA149 may offer more symptomatic relief than tiotropium and salmeterol/fluticasone. Similarly, the SPARK study in high (exacerbation) risk patients with severe or very severe disease showed that QVA149 was more effective than glycopyrronium in preventing moderate to severe exacerbations, and suggests that QVA149 may offer more symptomatic relief than LAMA monotherapy. Another phase III study comparing QVA149 with salmeterol/fluticasone in high-risk patients with moderate to very severe disease (FLAME) is ongoing. QVA149 is generally well tolerated, with no new safety signals identified compared with its monocomponents. Bronchodilators remain central to the symptomatic management of COPD. When dual bronchodilation is indicated, QVA149 offers the convenience of two bronchodilators in a single inhaler coupled with a simple, once-daily dosing regimen that may encourage better treatment adherence. Therefore, it is a valuable option in the treatment of COPD.

The manuscript was reviewed by: R. Buhl, Pulmonary Department, Mainz University Hospital, Mainz, Germany; M. Cazzola, Unit of Respiratory Clinical Pharmacology, Department of System Medicine, University of Rome “Tor Vergata”, Rome, Italy; R. Dahl, Allergy Centre, Odense University Hospital, Odense, Denmark; A.D. D’Urzo, Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; P.P. Montuschi, Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy; L.J. Nannini, Hospital de G Baigorria, Universidad Nacional Rosario, Rosario, Argentina; D.D. Spina, Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Biomedical and Health Sciences, King’s College London, London, England; A.M. Turner, QEHB Research Labs, University of Birmingham, Birmingham, England.